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We agree with Grant and Garland that, although existing
ecological studies support the findings of our meta-analysis of
observational studies, further work—especially that involving
well powered randomised intervention studies—is needed.1 2
However, the respective pooled risk ratios that we reported by
combining the primary and secondary prevention cohorts are
based on indirect comparisons (only a subset of studies provided
mortality risk data on people with pre-existing disease).
As Bolland and colleagues note, the overall estimates from the
vitamin D3 randomised controlled trials were indeed presented
as a combination of both active and inactive vitamin D3
supplements, given a lack of power in each component in
isolation.3 We also included a study that evaluated the effects
of vitamin D3 alone without concurrent administration of other
pharmacological interventions (which was similarly kept as a
vitamin D alone study in the earlier Cochrane report).1 4
Nonetheless, when this study and the other three calcitriol trials
were removed from the analyses,5-7 there was no significant
effect of “any vitamin D supplementation” on mortality (which
remains consistent with our original results). The pooled effect
estimate for the 10 vitamin D3 trials became slightly attenuated
(0.91, 95% CI 0.82 to 1.00) in our calculation; however, this
apparent inverse effect differed significantly from the
corresponding pooled estimate of vitamin D2 (P from
meta-regression analysis=0.03, for a comparison between
vitamin D3 and vitamin D2 trials). That said, we agree with
Bolland and colleagues that the selection criteria (such as
randomised v non-randomised, with calcium supplementation
v without) and decisions on subgroup analyses vary across
reviews on this topic, and this may explain the different findings
across these reports. However, as was discussed in our paper
(and the accompanying editorial), all these reviews (including
ours) are based on largely overlapping trials of mostly high risk,
elderly populations (with an average age >75 years in all trials
combined). Therefore, before any policy formulation, further
large scale and sufficiently prolonged trials with large samples
derived from the general population will be required.
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